Clinical Trials Using Pertuzumab

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical trials are research studies that involve people. The clinical trials on this list are studying Pertuzumab. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-20 of 20
  • NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma

    This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.
    Location: 1169 locations

  • My Pathway: A Study Evaluating Herceptin / Perjeta, Tarceva, Zelboraf / Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

    This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and / or are not suitable options per the treating physician's judgment.
    Location: 17 locations

  • I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

    The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic resonance imaging (MRI) images along with tissue and blood samples) are predictors of treatment success.
    Location: 14 locations

  • Trastuzumab Emtansine and Pertuzumab before Surgery in Treating Patients with HER2-Positive Stage II-III Breast Cancer

    This phase II trial studies how well trastuzumab emtansine and pertuzumab before surgery work in treating patients with human epidermal growth factor receptor 2 (HER2)-positive stage II-III breast cancer. HER2 is a protein found on the surface of cancer cells that helps them to grow and spread. Trastuzumab emtansine and pertuzumab may kill cancer cells by binding to HER2-positive on the surface of the tumor cells and blocking their ability to grow and spread.
    Location: 8 locations

  • Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer

    This is a Phase Ib, open-label, two-stage study with two active regimens in each stage designed to evaluate the safety and tolerability of combination treatment with atezolizumab, trastuzumab, and pertuzumab (with and without docetaxel) or atezolizumab and trastuzumab emtansine in participants with human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer (MBC) and locally advanced early breast cancer (EBC), and atezolizumab with doxorubicin and cyclophosphamide in HER2-negative breast cancer.
    Location: 8 locations

  • Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

    The primary objective of this study is to demonstrate that the combination of palbociclib with anti-HER2 therapy plus endocrine therapy is superior to anti-HER2-based therapy plus endocrine therapy alone in improving the outcomes of subjects with hormone receptor-positive, HER2+ metastatic breast cancer.
    Location: 10 locations

  • A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

    This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with other agents in a Genentech / Roche-sponsored parent study who are active and deriving benefit at the closure of parent study are eligible for continued treatment in this study.
    Location: 6 locations

  • Paclitaxel, Trastuzumab, and Pertuzumab before Surgery in Treating Patients with Inflammatory Breast Cancer

    This phase II trial studies how well paclitaxel, trastuzumab, and pertuzumab before surgery work in treating patients with inflammatory breast cancer. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as trastuzumab and pertuzumab, may interfere with the ability of tumor cells to grow and spread. Pertuzumab may also stop the growth of breast cancer by blocking blood flow to the tumor. Giving paclitaxel, trastuzumab, and pertuzumab may work better in treating breast cancer.
    Location: 6 locations

  • Taselisib and Anti-HER2 Therapy in Treating Patients with Advanced HER2+ Breast Cancer

    This phase Ib trial studies the side effects and best dose of taselisib when given with anti-human epidermal growth factor receptor 2 (HER2) therapies in treating patients with HER2 positive (HER2+) breast cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment. Taselisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as trastuzumab emtansine, pertuzumab, and trastuzumab, may block tumor growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Estrogen can cause the growth of breast cancer cells. Antihormone therapy, such as fulvestrant, may lessen the amount of estrogen made by the body. It is not yet known whether taselisib works better when given together with trastuzumab emtansine, pertuzumab, and trastuzumab, or with pertuzumab, trastuzumab, paclitaxel, and fulvestrant in treating patients with breast cancer.
    Location: 5 locations

  • TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

    The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers).
    Location: 4 locations

  • Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients with HER2-Positive Stage II-IV Breast Cancer

    This phase II trial studies how well pertuzumab, trastuzumab, and paclitaxel albumin-stabilized nanoparticle formulation work in treating patients with human epidermal growth factor receptor (HER)2-positive stage II-IV breast cancer. Monoclonal antibodies, such as pertuzumab and trastuzumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pertuzumab and trastuzumab together with paclitaxel albumin-stabilized nanoparticle formulation may be a better way to block tumor growth.
    Location: 3 locations

  • Atezolizumab, Paclitaxel, Trastuzumab, and Pertuzumab in Treating Patients with HER2 Positive Breast Cancer That Is Locally Recurrent, Metastatic, or Cannot Be Removed by Surgery

    This phase IIa trial studies the side effects of atezolizumab when given together with paclitaxel, trastuzumab, and pertuzumab and to see how well it works in treating patients with HER2 positive breast cancer that has come back at or near the same place as the original (primary) tumor, has spread to other places in the body, or cannot be removed by surgery. Monoclonal antibodies, such as atezolizumab, trastuzumab, and pertuzumab, may block tumor growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving atezolizumab, paclitaxel, trastuzumab, and pertuzumab may work better in treating patients with HER2 positive breast cancer.
    Location: Fox Chase Cancer Center, Philadelphia, Pennsylvania

  • Interferon Gamma-1b, Paclitaxel, Trastuzumab, and Pertuzumab in Treating Patients with HER-2 Positive Breast Cancer

    This phase I / II trial studies the side effects and best dose of interferon gamma-1b in combination with paclitaxel, trastuzumab, and pertuzumab in treating patients with HER-2 positive breast cancer. Interferon gamma-1b is a substance that can improve the body’s natural response and may interfere with the growth of tumor cells. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as trastuzumab and pertuzumab, may interfere with the ability of tumor cells to grow and spread. Giving interferon gamma, paclitaxel, trastuzumab, and pertuzumab may work better in treating HER-2 positive breast cancer.
    Location: Moffitt Cancer Center, Tampa, Florida

  • Paclitaxel and Carboplatin before Surgery in Treating Nigerian Women with Stage IIA-IIIC Breast Cancer

    This phase II trial studies how well paclitaxel works with carboplatin before surgery in treating Nigerian women with stage IIA-IIIC breast cancer before surgery. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois

  • Copper Cu 64-DOTA-Trastuzumab PET Imaging in Predicting Response to Treatment with Trastuzumab and Pertuzumab before Surgery in Patients with Locally Advanced HER2 Positive Breast Cancer

    This pilot clinical trial studies how well copper Cu 64-DOTA-trastuzumab positron emission tomography (PET) works in predicting response to treatment with trastuzumab and pertuzumab before surgery in patients with human epidermal growth factor receptor 2 (HER2) positive breast cancer that has spread from where it started to nearby tissue or lymph nodes. Diagnostic procedures, such as copper Cu 64 DOTA-trastuzumab PET, may help predict a patient’s response to trastuzumab and pertuzumab before surgery in patients with locally advanced HER2 positive breast cancer.
    Location: City of Hope Comprehensive Cancer Center, Duarte, California

  • Pertuzumab and Trastuzumab in Treating Patients with HER2 Positive Breast Cancer with Untreated Brain Metastasis

    This phase I trial studies the side effects and best dose of pertuzumab when given together with trastuzumab in treating patients with human epidermal growth factor receptor 2 (HER2) positive breast cancer that has spread to the brain. Pertuzumab and trastuzumab are drugs that stop breast cancer cells from growing abnormally by inhibiting (or blocking) certain types of proteins that include HER2.
    Location: Duke University Medical Center, Durham, North Carolina

  • Carboplatin and Paclitaxel with Pertuzumab and Trastuzumab or Bevacizumab in Treating Patients with Breast Cancer

    This phase II trial studies the side effects and how well carboplatin and paclitaxel given in combination with pertuzumab and trastuzumab or bevacizumab work in treating patients with breast cancer. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as pertuzumab, trastuzumab and bevacizumab, may interfere with the ability of tumor cells to grow and spread. Giving carboplatin and paclitaxel together with pertuzumab and trastuzumab or bevacizumab may kill more tumor cells.
    Location: UC Irvine Health / Chao Family Comprehensive Cancer Center, Orange, California

  • Paclitaxel, Trastuzumab, and Pertuzumab with or without Pembrolizumab in Treating Patients with Metastatic Breast Cancer

    This randomized phase III trial studies how well paclitaxel, trastuzumab, and pertuzumab with or without pembrolizumab works in treating patients with breast cancer that has spread to other parts of the body. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as trastuzumab, pertuzumab, and pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving paclitaxel, trastuzumab, and pertuzumab with pembrolizumab may kill more tumor cells.
    Location: NRG Oncology, Philadelphia, Pennsylvania

  • Neratinib and Paclitaxel with or without Pertuzumab and Trastuzumab before Combination Chemotherapy in Treating Patients with Metastatic or Locally Advanced Breast Cancer

    This phase I / II trial studies the side effect and best dose of neratinib and to see how well it works with paclitaxel and with or without pertuzumab and trastuzumab before combination chemotherapy in treating patients with breast cancer that has spread to other places in the body. Neratinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as pertuzumab and trastuzumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as paclitaxel, doxorubicin hydrochloride, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving neratinib, pertuzumab, trastuzumab, paclitaxel and combination chemotherapy may work better in treating patients with breast cancer.
    Location: M D Anderson Cancer Center, Houston, Texas

  • FDG-PET in Predicting Treatment Response in Patients with Newly Diagnosed Stage II-IV Breast Cancer Receiving Pertuzumab and Trastuzumab Prior to Surgery

    This phase II trial studies how well fludeoxyglucose F 18-positron emission tomography (FDG-PET) works in predicting treatment response in patients with newly diagnosed stage II-IV breast cancer receiving pertuzumab and trastuzumab prior to surgery. Diagnostic procedures, such as FDG-PET, may help measure and predict a patient's response to pertuzumab and trastuzumab prior to surgery.
    Location: 13 locations